Latest News

Stacy Pagos Haller, BrightFocus Foundation's President and CEO, urges the Food and Drug Administration to strongly support expanded use of neurodiagnostic tools to assess cognitive function.

Learn about a BrightFocus grantee's role in confirming amyloid's role in early Alzheimer's, a record-breaking $5.9 million in new Alzheimer's research awarded by BrightFocus Foundation, how to be prepared if you need to search for someone who has Alzheimer's disease, and more, in the winter edition of our Alzheimer's disease newsletter.

Research by BrightFocus grantee Matthew Campbell, PhD, of Trinity College Dublin, represents a potential new way to help clear the brain of a build-up of the toxic amyloid beta (Aβ) that leads to Alzheimer’s.

World Alzheimer’s Day finds us at a crossroads. We are confronted by a mounting global health and economic crisis. But we are also seeing encouraging signs from our laboratories, local communities, and halls of government.

BrightFocus Foundation today announced that its 2015 research program grants have been awarded to 58 scientists in 20 states and 7 foreign countries. Part of an $11 million research investment, the grants reflect the largest annual research funding in the foundation’s history.

Download the summer edition of our Alzheimer's disease newsletter and learn about a cancer drug that shows early promise as an Alzheimer's treatment, a new drug that passes early clinical trial tests in humans, and other helpful information.

Two BrightFocus grantees are honored by receiving the 2015 MetLife Foundation Awards in Medical Research, which work to stimulate novel investigations in the field of Alzheimer’s disease.